Keywords

• Ledipasvir Powder
• CAS 1256388-51-8
• 1256388-51-8

Quick Details

• ProName: Ledipasvir Powder CAS 1256388-51-8
• CasNo: 1256388-51-8
• Molecular Formula: 1256388-51-8
• Appearance: white powder
• Application: Animal Pharmaceuticals
• DeliveryTime: within 2-3 day
• PackAge: carton boc
• Port: tianjin/qingdao/shanghai
• ProductionCapacity: 1000000 Kilogram/Month
• Purity: 99%
• Storage: cool and dry
• Transportation: ship,fly
• LimitNum: 1 Gram
• Heavy metal: 1
• Grade: Industrial Grade
• 1: 100

Superiority

Hebei Mojin Biotechnology Co., Ltd,Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

Adenosine triphosphate can be used in the disease caused by tissue injury and activity reduction of ecto enzyme , including heart failure, carditis, miocardial infarction, cerebral arteriosclersis, coronary sclerosis, progressive muscular atrophy , cerebral hemorrhage , chronic hepatitis, cirrhosis of liver and hearing handicap, etc.

Details

Product Detailed

Introduction:

Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C.The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion, a hepatitis C virus protein.

Product picture



Packing &shipping&Payment

Shipping:by sea or by air
Payment:T/T,,moneygram
Packaging Details drum
Port:Tianjin
Lead Time :

Advantage
In stock